ACTRN12607000141448已完成3 期
A placebo-controlled, randomised phase III trial investigating the effects of oxytocin, a neuropeptide, on the neural circuit (i.e. amgydala) involved in threat processing in Generalised Social Anxiety Disorder using functional magnetic resonance imaging (fMRI).
School of Psychology, Psychiatry and Psychological Medicine, Monash University0 个研究点目标入组 40 人开始时间: 2007年2月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •Right-handed, non-smokers, psychotropic medication free for a minimum of 2 weeks (8 weeks for fluoxetine, 4 weeks for monoamine oxidase inhibitors), not taking hormonal contraceptives, and do not have comorbid alcohol or substance abuse or dependence. Additional inclusion for GSAD participants - Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) GSAD as primary diagnosis.
排除标准
- •Clinically significant medical or neurologic condition (not applicable to GSAD patients, see inclusion criteria), current/recent depressive episode, life history of bipolar, schizophrenia, obsessive compulsive disorder, post-traumatic stress disorder or presence of organic mental syndrome, mental retardation, or pervasive developmental disorder, pregnancy or lactation, presence of ferrous-containing metals within the body, inability to tolerate small, enclosed spaces without anxiety.
研究者
相似试验
进行中（未招募）
1 期
A Phase III randomised, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinomaAdvanced hepatocellular carcinomaMedDRA version: 7.1Level: LLTClassification code 10049010EUCTR2004-001773-26-GBBayer HealthCare AG, D-51368 Leverkusen Germany
已完成
3 期
A phase III randomised, placebo-controlled study of Sorafenib in repeated cycles of 21 days in combination with paclitaxel / carboplatin chemotherapy in patients with unresectable stage III or IV melanoma.nresectable stage III or IV melanoma.Unresectable stage III or IV melanoma.Cancer - Malignant melanomaACTRN12605000684628Bayer Australia Ltd250
进行中（未招募）
1 期
EMT2: EPA for Metastasis TrialColorectal cancer liver metastasesMedDRA version: 20.0Level: LLTClassification code 10007095Term: Cancer of liver, secondarySystem Organ Class: 100000004864EUCTR2016-000628-24-GBniversity of Leeds448
已完成
不适用
Clot lysis: evaluating accelerated resolution of intraventricular haemorrhage Phase IIIIntraventricular haemorrhage (IVH) or IVH with intracerebral haemorrhage (ICH)Circulatory SystemIntracerebral haemorrhageISRCTN70157009Individual Sponsor (USA)500
进行中（未招募）
不适用
A Phase III randomized, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinomaEUCTR2004-001773-26-DEBayer HealthCare AG, D-51368 Leverkusen Germany560